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Summary 
Hypergonadotropic ovarian dysgenesis (ODG) with 
normal karyotype is a heterogeneous condition that in 
some cases displays Mendelian recessive inheritance. 
By systematically searching for linkage in multiplex 
affected families, we mapped a locus for ODG to chro- 
mosome 2p. As the previously cloned follicle-stimulat- 
ing hormone receptor (FSHR) gene had been assigned 
to 2p, we searched it for mutations. A C566T transition 
in exon 7 of FSHR predicting an Ala to Val substitution 
at residue 189 in the extracellular ligand-binding do- 
main segregated perfectly with the disease pheno- 
type. Expression of the gene in transfected cells dem- 
onstrated a dramatic reduction of binding capacity and 
signal transducUon, but apparently normal ligand- 
binding affinity of the mutated receptor. We conclude 
that the mutation causes ODG in these families. 
Introduction 
Normal gonadal function is critically dependent on the in- 
tegrity of the pituitary-gonadal xis. A key role in this regu- 
latory circuit is played by the two pituitary gonadotropins, 
luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH). In the prepubertal ovary, follicular development is 
arrested before maturation, resulting in follicular atresia 
until the onset of gonadotropin stimulation at puberty in- 
duces follicular maturation and ovulation. Arrest of ovarian 
maturation at puberty can occur as a result of failure of 
gonadotropin secretion or as a lack of ovarian response 
to the tropic stimulation. Clinically, both conditions are 
characterized by normal prepubertal development with an- 
atomically normal internal and external genitalia, variably 
developed secondary sex characteristics, and primary 
amenorrhea. When the failure of ovarian development is 
caused by lack of ovarian response, the circulating levels 
of FSH and LH are elevated, owing to missing gonadal 
negative feedback (hypergonadotropic hypogonadism). In 
conjunction with poorly developed streak ovaries, this con- 
dition has been labeled gonadal or ovarian dysgenesis 
(ODG), in spite of the intact sex determination (Simpson 
et al., 1971; Simpson, 1979). The term is descriptive and 
does not indicate any causative mechanism. 
Ovarian dysgenesis with normal XX karyotype is be- 
lieved to be rare and mostly sporadic. However, by compil- 
ing and analyzing the published data on ovarian dysgene- 
sis with elevated FSH, Simpson et al. (1971) concluded 
that some cases are likely to be caused by autosomal 
recessive mutations. Indeed, results of a population-based 
study of ODG in the Finnish population disclosed as many 
as 75 cases, allowing the incidence of the condition to be 
estimated as 1 in 8, 300 females. Moreover, the recessive 
mode of inheritance was confirmed by segregation analy- 
sis, by the existence of several kindreds with two or more 
affected sisters, and by genealogical studies showing a 
clear-cut founder effect in an isolated subpopulation of the 
country (Aittom~iki, 1994). The locus was named ODGI. 
In this paper, we describe a series of investigations un- 
dertaken to determine the genetic and molecular basis of 
ODG. We took advantage of the existence of multiplex 
families in Finland that allowed us to map a locus to chro- 
mosome 2p by a systematic search for linkage. This fo- 
cused our attention on the FSH receptor (FSHR) gene, 
which had previously been cloned (Sprengel et al., 1990; 
Minegishi et al., 1991; Kelton et al., 1992) and mapped 
to 2p16-21 (Rousseau-Merck et al., 1993; Gromoll et al., 
1994). By sequencing the coding regions of the gene, we 
found a missense mutation in the region encoding the 
extracellular ligand-binding domain of the receptor that 
segregated perfectly with the phenotype in affected fami- 
lies. Transfection experiments howed that the mutation 
leads to dramatically reduced binding capacity and cyclic 
adenosine 3', 5'-monophosphate (cAMP) production after 
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Figure 1. Pedigrees, Alleles, and Haplotypes of Six Multiplex Families 
Open squares, unaffected males. Open circles, unaffected females. 
Closed circles, affected females. Alleles at the polymorphic markers 
are arranged into most likely haplotypes. The allele at the disease- 
causing C566T mutation is shown at the bottom of each haplotype. 
FSH stimulation, in the face of apparently normal binding 
affinity in cells expressing the mutated receptor protein. 
These studies prove that a recessively inherited mutation 
of the FSHR gene causes a hereditary form of hypergona- 
dotropic ovarian failure by possibly interfering with traffick- 
ing of the receptor to the cell surface or with its rate of 
degradation. 
Results 
Linkage 
Of the available 37 samples from six multiplex families, 
30 were used in the initial search for linkage. As male 
sibs were not informative for the phenotype,'they were not 
included in the initial search, but in subsequent linkage 
analyses, six males and one further healthy female sib 
were included (Figure 1) to contribute haplotype informa- 
tion. The male sibs were coded phenotype unknown. As 
fathers can be presumed to be heterozygous rather than 
homozygous for the mutation responsible for a recessive 
trait, their phenotype was coded unaffected. 
After studying 47 markers, we noted preliminary evi- 
dence of linkage for the markers D2S134 and D2S177. 
The linkage was confirmed by using markers D2S119 and 
D2S123, located between the former markers and flanking 
an approximately 12 cM genetic region of chromosome 
2. This interval was further studied with four additional 
markers, D2S391, D2S288, CA21, and CA7, located in the 
above defined interval. 
The results of the pairwise linkage analyses in the multi- 
plex families are shown in Table 1. There were altogether 
46 potentially informative meioses in the six families, and 
of these, 30 were in affected family members. It is evident 
from the Iod scores shown that there were no recombina- 
tions between any of the marker loci and ODGI. The high- 
est Iod score, Zma~ = 4.71, was obtained for the marker 
D2S391, while two of the other marker loci, D2S288 and 
CA21, also gave Iod scores exceeding the formal limit of 
proven linkage (Z/> 3.00). 
Haplotype Analysis 
Alleles at the most informative closely linked markers were 
arranged into most likely haplotypes as shown in Figure 
1. For markers CA21, CA7, and D2S123, the haplotype 
1-4-4 was associated with the disease in most chromo- 
somes. This can be considered the ancestral disease- 
associated haplotype. The only other disease-associated 
haplotype, 2-4-4, occurred in the maternal chromosome 
in family 5 and the paternal chromosome in family 6. As 
marker CA21 showed no recombinations with the pheno- 
type, these two chromosomes most likely represent histor- 
ical crossovers between the disease mutation and marker 
CA21, which thus defines the distal border of the interval 
in which the mutated gene must be located. The proximal 
border of the disease gene interval was marker CA18, in 
which a recombination was detected (data not shown). 
The genetic length of the critical interval (CA21 to CA18) 
is approximately 10.5 cM (Leach et al., 1994; Gyapay et 
al., 1994; Hemminki et al., 1994). The detection of an ex- 
Table 1. Pairwise Logarithm of Odds (Lod) Scores between ODG1 and Seven Linked Chromosome 2p Marker Loci in Six Multiplex Families 
Marker Locus 
Recombination 
Fraction (e) D2S119 D2S391 D2S288 CA21 CA7 D2S123 FSHR1 
0.00 2.41 4.71 3.10 4.20 2.66 2.68 2.72 
0.001 2.41 4.70 3.10 4.19 2.66 2.67 2.71 
0.01 2.35 4.59 3.03 4.11 2.60 2.62 2.66 
0.05 2.12 4.14 2.72 3.74 2.35 2.39 2.44 
0.10 1.82 3.56 2.33 3.24 2.03 2.08 2.14 
0.20 1.20 2.38 1.52 2.19 1.36 1.44 1.49 
0.30 0.62 1.26 0.78 1.16 0.71 0.79 0.82 
90% support i nte rval 0-0.17 0-0.09 0-0.13 0-0.10 0-0.16 0-0.16 0-0.16 
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tended conserved haplotype in all affected chromosomes 
from the six families suggests that they all share one an- 
cestral disease-causing mutation. This is compatible with 
previously described genealogical evidence that many of 
the ancestors originated in a limited subpopulation in the 
north central region of Finland (Aittom&ki, 1994). 
FSHR as a Candidate for ODG 
Genes that had been assigned to the ODG 1 region in chro- 
mosome 2p were the gonadotropin receptor genes, that 
is, FSHR (Rousseau-Merck et al., 1993; Gromoll et al., 
1994) and the LH receptor gene (LHR) (Rousseau-Merck 
et al., 1990). Both had already been cloned (Minegishi et 
al., 1990; Sprengel et al., 1990; Jia et al., 1991 ; Minegishi 
et al., 1991; Kelton et al., 1992). 
The receptors for FSH and LH, together with the recep- 
tor for the third pituitary glycoprotein hormone, the thyroid- 
stimulating hormone receptor (TSHR), form a subgroup of 
the large G protein-coupled receptor family. Their protein 
structure comprises three distinct domains, the extracel- 
lular ligand-binding domain, the transmembrane domain 
consisting of seven membrane-spanning regions with six 
intervening loops, and finally, the intracellular COOH- 
terminal domain (Figure 2). A highly conserved structure 
II `NH2 exonl 
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Figure 2. Schematic Representation ofthe Structure of FSHR 
Ec, extracellular domain; Tc, transmembrane domain; Ic, intracellular 
domain. Exons are denoted by alternating black color and stippling. 
Asterisks denote glycosylation sites. The insert in exon 7 shows the 
site of the C566T mutation leading to a substitution ofAla-189 to Val. 
The insert in the part of exon 10 encoding the COOH-terminus shows 
the G2039A transition polymorphism designated FSHRI. Modified 
from Sprengel et al. (1990). 
shared by the G protein-coupled receptors is the trans- 
membrane domain. The distinctive feature of FSHR, LHR, 
and TSHR is their large extracellular ligand-binding do- 
main. The FSHR gene contains 10 exons. The first nine 
exons encode the extracellular domain, whereas the trans- 
membrane and intracellular domains are encoded by the 
terminal exon 10 (Sprengel et al., 1990; Heckert et al., 
1992). Disease-causing mutations in the genes encoding 
glycoprotein hormone receptors have been identified in 
the well-conserved regions coding for the transmembrane 
domain, e.g., activating (Kremer et al., 1993; Shenker et 
al., 1993; Yano et al., 1995) and inactivating mutations 
of the LHR gene (Kremer et al., 1995) and an activating 
mutation of the TSHR gene (Duprez et al., 1994), all leading 
to distinct disease phenotypes: familial male precocious 
puberty (FMPP), familial male pseudohermaphroditism, 
and nonautoimmune autosomal dominant hyperthyroid- 
ism, respectively. In view of the central role of FSH in the 
stimulation of ovarian follicular development, we initiated 
a search for mutations in FSHR. 
Screening for Mutations by Denaturing Gradient Gel 
Electrophoresis: A Polymorphism in FSHR 
To screen for mutations in the large terminal exon 10 
of FSHR with denaturing gradient gel electrophoresis 
(DGGE), this exon was amplified with GC-clamped primers 
in four different polymerase chain reaction (PCR) reac- 
tions with overlapping products covering the entire trans- 
membrane and intracellular domains. A DGGE change 
was detected in the terminal region of exon 10. The same 
PCR reaction was repeated with a labeled primer for se- 
quencing. In the sequenced product, a G2039A transition 
was detected in the region encoding the intracellular do- 
main, predicting a change of Ser-680 to Asn. This change 
had previously been identified as a difference between 
the ovarian and testicular sequence for the FSHR gene 
(Kelton et al., 1992). By DGGE analysis, a mother of a 
large sibship and a healthy female sib were both homozy- 
gous for the same allele as were the affected individuals, 
implying that this was not a disease-causing mutation (Fig- 
ure 3). Conclusive evidence that this was not a mutation 
was obtained when the multiplex families were studied for 
the two alleles by restriction fragment length polymor- 
phism analysis (see Figure 1). This polymorphism (desig- 
nated FSHR1) was subsequently exploited as a marker in 
the linkage analysis and showed no recombinations with 
the disease phenotype (Table 1). 
Search for Mutations by Sequencing 
After excluding mutations in exon 10, we proceeded by 
screening the other exons by amplifying each exon with 
flanking intronic primers and sequencing the PCR prod- 
uct. With this method, mutations could be sought and ex- 
cluded in exons 1, 2, 3, 4, 5, and 9. While working on 
the remaining exons for which complete sequences of the 
flanking introns were not available, it turned out that it was 
possible to amplify mRNA of the FSHR gene by using RNA 
from blood leukocytes as template. It has been reported 
that a low level of mRNA synthesis occurs in white blood 
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Figure 3. Denaturing Gradient Gel Electrophoresis Showing Segre- 
gation of G2039A Polymorphism in Two Families 
Pedigree symbols as in Figure 1. In the family on the left, the mother 
and youngest daughter are heterozygous GA (two heteroduplexes), 
while the two affected daughters are homozygous GG. In the family 
on the right, one unaffected daughter is heterozygous GA, while the 
mother and three other daughters are homozygous GG. 
cells for at least some and perhaps most tissue-specific 
genes (Sarkar and Sommer, 1989); this phenomenon has 
been called illegitimate transcription (Chelly et al., 1989). 
Since PCR is an extremely sensitive technique, and it is 
possible to identify mutations by direct sequencing of PCR 
products, we decided to isolate RNA from blood cells, am- 
plify exons 6-9  by reverse transcription-PCR (RT-PCR), 
and sequence the product directly• All the affected individ- 
uals were found to be homozygous for a C to T transition 
at position 566, which predicts a change of Ala-189 to 
Val (Figure 4). It was noticed that the mutation C566T 
abolishes a restriction site of Bsml. By restriction diges- 
tion, the families could now be screened for the mutation. 
When these data were compared with the linkage results, it 
was noted that the disease haplotype segregated perfectly 
with the mutation. All the affected individuals displaying 
the disease haplotype were homozygous for the mutation, 
and all the parents (obligatory heterozygotes) that could 
be studied proved to be heterozygous for the mutation 
(Figure 5). In every individual studied, the affection status, 
the result of the haplotype analysis, and the status of the 
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Figure 4. Sequence Analysis of the C566T Mutation 
Left, wild-type (CC); middle, heterozygous (CT); right, affected (TT). 
Figure 5. Segregation of C566T Mutation in Family 7 Determined by 
Restriction Fragment Length Polymorphism Analysis 
Pedigree symbols as in Figure 1. A PCR product 78 bp in length com- 
prising nucleotide 566 in exon 7 was digested with Bsml and electro- 
phoresed. In the wild-type situation (CC), the PCR product is cleaved 
into fragments 51 bp and 27 bp in length (seen in both unaffected 
sibs). The mutation abolishes the Bsml cleavage site so that both 
homozygous sibs (1-1) show only the 78 bp fragment. The heterozy- 
gous parents (CT) show all three fragments. 
C566T mutation were concordant. This allowed us to con- 
clude tentatively that the C to T transition in exon 7 of the 
FSHR gene causes ODG in the families studied. 
Functional Studies of the Mutated Receptor 
Recombinant human FSH (rhFSH) induced a 3- to 4-fold 
dose-dependent stimulation of cAMP production in immor- 
talized mouse Sertoli cells (MSC-1) transfected with wild- 
type human FSHR plasmid (Figure 6). The ED~o of the 
stimulant was approximately 75 IU/liter. In contrast, when 
cells transfected with the mutated FSHR plasmid, or only 
with pCMV-luci, were studied in the same fashion, only 
negligible FSH effect on CAMP production was observed. 
In the FSH binding assay, Scatchard analysis revealed, 
after correction for transfection efficiency, a 28-fold higher 
number of receptors per cell in the MSC-1 cells transfected 
with the wild-type receptor plasmid than in cells trans- 
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Figure 6. FSH-Stimulated cAMP Production of MSC-1 Cells Trans- 
fected with the FSHR Expression Constructs :.. 
Squares denote wild-type, circles mutant, and triangles mock-trans- 
fected controls. Each batch of cells was cotransfected with the pCMV- 
luci expression plasmid, and the cAMP production was equalized to 
a constant amount of luciferase expression and calculated p r 106 
cells after a 3 hr incubation. Each point is the mean of duplicate incuba- 
tions, and one of three similar experiments is presented. 
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Figure 7. ScatchardAnalysisof[~2Sl]lodo-FSH Binding to Transfected 
MSC-1 Cells 
Circles denote wild-type and triangles (insert) FSHR expression con- 
structs. In each case, 2 x 10 s transfected cells were incubated in 
triplicate with increasing concentrations oflabeled FSH in a total vol- 
ume of 250 ~1. The cells were cotransfected with the pCMV-luci expres- 
sion plasmid, and the specific binding was equalized to a constant 
amount of luciferase activity. After these corrections, the cell suspen- 
sion transfected with the wild-type FSHR construct displayed 18.2 
pmol/liter, and that expressing the mutated construct, 0.63 pmol/liter 
of specific FSH binding. The equilibrium association constants (K~) of 
FSH binding in the same cell preparations were 6.7 x 109 mol/liter 
and 4.8 x 10 ~ mol/liter, espectively. One of two similar experiments 
is presented. 
fected with the plasmid encoding the mutated receptor. 
The equilibrium association constant (Ka) of FSH binding 
was 6.7 x 109 mol/liter with the wild-type receptor and 
very similar, 4.8 x 109 mol/liter, with the mutated receptor 
(Figure 7). The results agree well with the affinity mea- 
sured for FSH binding in human testicular homogenate 
(WahlstrSm et al., 1983). These studies confirmed the 
pathogenetic role of the C566T mutation that severely in- 
terferes with the signal transduction, but apparently has 
no effect on affinity of the remaining small number of re- 
ceptors capable of ligand binding. 
Discussion 
Hypergonadotropic hypogonadism accounts for up to 
some 40% of the patients with primary amenorrhea (Rein- 
dollar and McDonough, 1984). Many of these cases are 
due to abnormalities of the sex chromosomes. In the pres- 
ence of a normal karyotype female, hypergonadotropic 
hypogonadism is a heterogeneous condition (Reindollar 
and McDonough, 1984; Aiman and Smentek, 1985; Rebar 
and Connolly, 1990). We were able to collect 75 females 
with hypergonadotropic ODG and were able to map the 
ODG1 locus to chromosome 2p by linkage. This localiza- 
tion turned out to coincide with the region where FSHR 
and LHR had previously been assigned. Both genes were 
possible candidate genes for ODG. On the basis of data 
collected by interviewing the female patients, there were 
no male sibs known to be affected with hypogonadism. 
This favored the hypothesis that the disease in these fami- 
lies was not due to an LHR mutation, which would be likely 
to cause severe hypogonadism (pseudohermaphroditism) 
in affected males (Kremer et al., 1995). Subsequently, a 
mutation was located in exon 7 of the FSHR gene and was 
demonstrated to cause failure of signal transduction of the 
receptor. 
Mutation Effect on Structure and Function 
of the Receptor Protein 
The FSHR gene has 10 exons, which encode three distinct 
protein domains (Figure 2). The amino acid substitution 
Ala to Val is located in a region that is highly conserved 
when compared with the FSHR of the monkey, sheep, and 
rat (Sprengel et al., 1990; Gromoll et al., 1993; Yarney 
et al., 1993); therefore, it must be functionally important. 
Moreover, it belongs to a sequence of five amino acids 
that are identical in the FSHR, LHR, and TSHR and contain 
a consensus N-linked glycosylation site (Nagayama et al., 
1989; Minegishi et al., 1990, 1991), also pointing to the 
functional importance of this region. Because of conserva- 
tion of the mutated region in receptors of the three glyco- 
protein hormones, it may not be the site of ligand recogni- 
tion and binding. More likely, it plays a role in transfer of 
the receptor to the plasma membrane, or its turnover, 
since the affinity of the low number of mutated receptors 
expressed upon transfection was normal. 
Most previously described disease-causing mutations 
of the G protein-associated receptor family and the glyco- 
protein hormone receptor subgroup have been located in 
the transmembrane region. All activating and inactivating 
LHR mutations o far reported have been in the sixth trans- 
membrane sequence (Shenker et al., 1993; Kremer et al., 
1993, 1995; Yano et al., 1995). Interestingly, the only inac- 
tivating LHR mutation reported (Kremer et al., 1995) 
caused similar drastic reducton of binding capacity with 
unaffected affinity as was found here with the FSHR mu- 
tated in the region encoding the extracellular domain. 
The mutation described here is adjacent o a glycosyla- 
tion site of the FSHR that is essential for FSH binding. At 
least one of the two essential glycosylation sites has to 
be glycosylated for the binding of FSH to occur (Davis et 
al., 1995). It is therefore also possible that the mutation 
could act by hindering the necessary glycosylation. A com- 
puter-simulated structural prediction did not reveal any 
obvious change of the secondary or tertiary protein struc- 
ture (data not shown). Hence, the mechanism by which 
the relatively unremarkable Ala to Val change brings about 
the dramatic suppression of binding capacity and signal 
transduction observed upon transient expression of the 
mutated FSHR cDNA remains to be explored. It will be of 
interest to determine whether the resulting low binding 
capacity with apparently normal binding affinity is due to 
deficient ranslation, intracellular trafficking, ligand-bind- 
ing, or accelerated receptor degradation. 
Physiologic Effects of FSH 
The notion that initiation of follicular growth is independent 
of gonadotropin stimulation is supported by the persis- 
tence of initial growth in gonadotropin-deficient mice (Hal- 
pin et al., 1986) and by its occurrence in the perinatal rat 
ovary before the appearance of gonadotropin receptors 
(Sokka and Huhtaniemi, 1990; Rannikko et al., 1995). At 
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the time of puberty, the interrupted process of follicular 
growth is overcome when cyclic ovarian function ensues. 
The most important hormonal event at that time is the 
increase in FSH secretion, which rescues a group of folli- 
cles from atresia. The receptors for FSH are exclusively 
present in the granulosa cells of developing follicles (Rich- 
ards, 1995). When FSH binds to its receptor, it activates 
the production of estrogen in granulosa cells and also stim- 
ulates their growth, initiating a normal ovulatory cycle (La- 
Polt et al., 1992; Tilly et al., 1992). The ability of FSH to 
induce follicular development has been demonstrated in 
women with gonadotropin deficiency (Couzinet et al., 
1988). Thus, FSH seems to have a pivotal role in the devel- 
opment of the quiescent prepubertal ovary into a mature, 
cycling, and hormonally active organ. If this indispensable 
FSH action does not take place, follicular growth is ar- 
rested, atresia continues, and with the lack of normal cyclic 
ovarian function, it leads to the syndrome of hypergonado- 
tropic primary amenorrhea, that is, ODG as defined here. 
Failure of the action of either FSH or its receptor has 
been proposed to cause a type of hypergonadotropic hy- 
pogonadism designated the resistant ovary syndrome 
(Jones and Moraes-Ruehsen, 1969; van Compenhout et 
al., 1972; Maxson and Wentz, 1983). In this rare condition, 
the ovarian histology displays primary follicles with ar- 
rested development. A mutation of the 15 subunit of FSH, 
leading to the inhibition of the binding of the hormone with 
its receptor, indeed appeared to cause primary amenor- 
rhea and infertility in a patient (Matthews et al., 1993) with 
the resistant ovary syndrome. This patient was homozy- 
gous for a deletion of two nucleotides in exon 3 of the FSH 
gene. The ovarian histology was not described, but the 
patient conceived after treatment with FSH. The mother 
of the patient was an obligatory heterozygote and had 
been amenorrheic and infertile for six years before the 
conception of her only child. In contrast, the mutation in 
the FSHR gene described here does not seem to affect 
ovarian function in the heterozygous tate. The mothers 
who are obligatory and experimentally proven heterozy- 
gotes have many children, as demonstrated by the pedi- 
grees in Figure 1. 
In the male, FSH is needed for pubertal proliferation of 
Sertoli cells and for initiation of spermatogenesis, as well 
as for maintenance of qualitatively normal spermatogene- 
sis of the adult testis. However, normal FSH action is not 
an absolute requirement for spermatogenesis, which can 
be maintained at near normal levels with testosterone 
alone in the absence of FSH (Matsumoto, 1989; Wein- 
bauer and Nieschlag, 1993; Zirkin et al., 1994). What effect 
might the FSHR mutation described here have in men? 
Gonadal dysgenesis has been reported at least twice 
in a brother of an affected ODG female. Both of these men 
had small testes, normal serum testosterone, high serum 
FSH, and azoospermia (Smith et al., 1979; Granat et al., 
1963). By direct mutational analysis, it is now possible to 
determine the mutation status of males and perform a 
clinical study on those who are homozygous for the muta- 
tion. As we have not yet taken t his step, for ethical reasons, 
we do not have conclusive data on the phenotype of the 
brothers. However, as shown in Figure 1, blood samples 
were initially obtained from six consenting brothers of pro- 
bands belonging to the six multiplex families that we stud- 
ied for linkage. As can be seen in Figure 1, the mutation 
status has been determined in these males. All three 
males who are homozygous for the mutation are over 40 
years of age. Two of them have two children each, while 
the third is childless and is said to have sought medical 
help for infertility. These preliminary data rule out obliga- 
tory sterility and tentatively predict that spermatogenesis 
in the males homozygous for the mutation might vary any- 
where from azoospermia to normospermia. 
Incidence and Worldwide Distribution 
We demonstrate here that hypergonadotropic hypogo- 
nadism with normal female karyotype is caused by a muta- 
tion in the FSHR gene and that the condition is inherited 
in a regular recessive Mendelian fashion. While this study 
was conducted on families in which at least two female 
sibs were affected, it follows that sibships with a single 
affected female (so-called sporadic cases) must also oc- 
cur. In our previous study, many such patients were indeed 
detected, and the segregation ratio was 0.23, close to that 
expected for a recessive condition (Aittom~ki, 1994). Many 
of the probands were derived from geographically defined 
subpopulations in Finland by an approach that aimed at 
as complete an ascertainment as possible. The result al- 
lowed the minimum incidence of the condition to be calcu- 
lated as 1 in 8300 females. This translates into a carrier 
frequency of 1 in 45. If similar figures occur in other popula- 
tions, ODG will turn out to be one of the commonest reces- 
sively inherited diseases of mankind. 
It needs to be determined whether the incidence of this 
entity is as high in other populations as in Finland. A well- 
known feature of the Finnish population is a considerable 
enrichment of mutations for certain recessively inherited 
disorders (Norio, 1981 ; de la Chapelle, 1993). The mecha- 
nism of enrichment is that of founder effect, population 
bottlenecks, and genetic drift in the genetically isolated 
Finnish population. Moreover, regional subisolates in Fin- 
land often show even higher gene frequencies than the 
population as a whole (Nevanlinna, 1972; de la Chapelle, 
1993). As this feature is typical of ODG in Finland as well 
(Aittom&ki, 1994), it is possible that a considerable enrich- 
ment of the causative ancestral mutation has occurred. 
Given the above findings, what proportion of women 
with primary amenorrhea is likely to have ODG caused by 
a mutation in the FSHR gene? Clearly, it is too early to 
answer the question, but fortunately a tool is now available 
to provide the answer. We anticipate that as a first step, 
mutational analysis of the FSHR gene will be practiced 
in women with otherwise unexplained hypergonadotropic 
primary amenorrhea. As more data on the mutational 
spectrum become available, it may be possible to narrow 
the search to a defined part of the gene. Eventually, sim- 
pler methods will undoubtedly be developed for clinical use. 
As to the worldwide incidence and distribution of the 
condition, we hypothesize that it exists in different popula- 
tions, as shown by the existence of occasional multiplex 
FSHR Mutation in Hypergonadotropic Ovarian Failure 
965 
fami l ies in Europe,  North Amer ica ,  and South Amer ica  
(S impson et al., 1971). We also hypothes ize  that the inci- 
dence  of the condi t ion may be ser ious ly  underest imated  
in cl inical pract ice,  as seems to have been the case in 
Finland, where  a comprehens ive  populat ion-wide study 
led to the d iscovery  of many prev ious ly  und iagnosed  pa- 
t ients (Aittom&ki, 1994). 
Different Types of Mutations: Genotype-Phenotype 
Correlations 
We look forward to determin ing  whether  other  mutat ions 
of  the FSHR gene might a lso cause  hypergonadot rop ic  
hypogonad ism.  We shall  p roceed by test ing the sporad ic  
pat ients d iagnosed  prev ious ly  (Aittom~_ki, 1994). We antic- 
ipate f inding some of these pat ients to be homozygous  
for the C566T mutat ion,  whi le others  may be heterozygous  
for it. In heterozygous  patients,  the FSHR gene on the 
other  chromosome will be carefu l ly  searched for other  mu- 
tations. These  s tud ies  will a l low the degree  of  al lel ic heter- 
ogene i ty  in ODG to be assessed ,  as well as the proport ion 
of ODG pat ients that are not due to FSHR mutat ions  (ge- 
netic heterogenei ty)  to be determined.  Moreover ,  these  
data  will a l low genotype-phenotype  corre lat ions  to be 
made.  Finally, the effects of the mutat ion on spermatogen-  
esis need fur ther  study. 
Experimental Procedures 
Patients and Families 
To identify patients with ovarian dysgenesis, the registries of hospitals 
as well as cytogenetic laboratories were screened for patients with 
amenorrhea, as described in detail previously (Aittom~ki, 1994). 
Among the 75 patients who met the diagnostic criteria described be- 
low, 15 belonged to six multiplex families (Aittom~ki, 1994). Samples 
were available from 37 individuals belonging to these six families 
(Figure 1). 
Diagnostic Criteria 
The following five criteria were used for final selection: first, primary 
amenorrhea or secondary amenorrhea before the age of 20 years; 
second, normal karyotype (46, XX); third, high concentration of serum 
gonadotropins (FSH at least 40 IU/liter); fourth, date of birth between 
the years 1950 and 1976 (only when there were multiple affected indi- 
viduals in the family were all affected individuals included irrespective 
of age); and fifth, no other known cause of the hypergonadotropic 
hypogonadism. 
Samples 
Samples of venous blood (10-20 ml) were collected from each con- 
senting individual. DNA was extracted by standard methods (Sam- 
brook et al., 1989). Total RNA was isolated from fresh leukocytes or 
lymphoblastoid cell lines established from these patients (Chomczyn- 
ski and Sacchi, 1987). 
Polymorphic Microsatellite Typing 
The markers used initially were Genethon microsatellite markers 
(Weissenbach et al., 1992; Gyapay et al., 1994) that were chosen at 
approximately 20 cM intervals for a systematic search for linkage. 
Further markers used were CA21, CA7, and CA18 (Leach et al., 1994; 
Hemminki et al., 1994). Finally, the G2039A change located in exon 
10 of the FSHR gene that we found was designated FSHR1 and used 
as a polymorphic marker to confirm the linkage. The PCR conditions for 
most of the microsatellite markers were as described before (Sankila et 
al., 1995). 
Linkage Analysis 
Pairwise linkage analyses were carried out with the MLINK subpro- 
gram of the LINKAGE program package (Lathrop et al., 1984). Marker 
allele frequencies were set as estimated in the normal chromosomes 
by subprogram ILINK. The disease allele frequency was set to 0.01, 
and the Iod scores were computed under a model of equilibrium be- 
tween the disease locus and each of the marker loci, assuming reces- 
sive mode of inheritance with full penetrance in females. Male sibs 
were assigned affection status unknown. 
DGGE 
For mutation screening of the transmembrane and intracellular do- 
mains of the large exon 10 of the FSHR gene, four separate PCR 
reactions with overlapping PCR products were amplified. Pairs of GC- 
clamped primers (Table 2, primers 10-13) were optimized for each 
fragment with the MELT 87 program (Lerman and SiIverstein, 1987) 
and analyzed with DGGE (Myers et al., 1988). A 40 bp GC-clamp (CGC,- 
CCGCCGCGCCCCGCGCCCGGCCCGCCGCCCCCGCCCG) was at- 
tached to either end of the primer according to the predicted melting 
curve. A polyacrylamide denaturing el was designed for each ampli- 
fied fragment with a linear concentration gradient (,~ 20%-30%) of 
the denaturants (formamide and urea) and was run in an aquarium at 
a stable temperature of 60°C for 16-20 hr in a commercially available 
apparatus (denaturing gradient gel electrophoresis ystem, model 
DGGE-2000, C. B. S. Scientific Company). 
Sequencing and Restriction Enzyme Analysis 
For sequencing of the observed DGGE change in exon 10 of the FSHR 
gene, a fragment of 326 bp corresponding to nucleotides 1818-2143 
(Minegishi et al., 199f; Kelton et al., 1992) was amplified with a different 
forward primer (Table 2, primers 14) under the same PCR conditions 
as before and sequenced as described below. A change of G to A 
was identified in nucleotide 2039, abolishing a restriction site for Bbsl. 
For screening of the two alleles, the amplified DNA fragment was 
digested with Bbsl (New England Biolabs), and the fragments were 
electrephoresed in a 2% agarose gel. 
cDNA Synthesis 
Total RNA was isolated from lymphoblasts or leukocytes. RNA (0.8 
I~g) was used as a template for first-strand cDNA synthesis and primed 
for reverse transcription by using 40 pmol of a specific reverse primer 
(Table 2, primer 15.r). Moloney murine leukemia virus (MoMLV) re- 
verse transcriptase buffer (Promega), dNTPs (to 1 raM), 20 U of RNAsin 
(Promega), and MoMLV reverse transcriptase (200 U) were added in 
a final volume of 20 I~1 and the samples incubated at 42°C for 1 hr. 
The samples were heated to 95°C for 10 rain, and a 5 p_l aliquot of 
the resulting product was used as template for PCR as described 
below. 
RT-PCR 
cDNAs were amplified by two rounds of PCR using a nesting strategy 
to enhance yield and specificity, in the first round, the previously used 
reverse primer and a new forward primer (Table 2, primer 16) were 
used to produce a 2082 bp product. 
For the second round, 5 p,I of the first round product was used as 
template for amplification using two internal primers for exons 6-9 
(Table 2, primers 6). In this case, a PCR product of 357 bp was ob- 
tained. 
PCR Amplification from Genomic DNA for Mutation Detection 
To amplify exons f, 2, 3, 4, 5, 9, and the extracellular egion of exon 
10 of the FSHR gene, primers flanking each exon and the extracellular 
region of exon 10 were used (Table 2, primers 1-5, 8, and 9). The 
specific PCR conditions and the cycling parameters for each reaction 
are available from the authors on request. For the size of each PCR 
product, see Table 2. 
To amplify a suitable segment of the FSHR gene containing nucleo- 
tide 588 (Kelton et al., 1992), primers flanking the region were used 
(Table 2, primers 7). A 78 bp product is amplified from genomic DNA 
by this procedure. 
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Table 2. Primers Used in the Study 
Number Primer Sequence Exon Product Size Primer Location 
1 Forward: 5'-AATTATGGCCTGCTCCTG-3' 1 215 bp -4-intronic ~ 
Reverse: 5'-ATAGTACGCAATG CACAAATGC-3' 
2 Forward: 5'-TCTTTGCAGGAGGTTTGTCC-3' 2 118 bp Intronic ~ 
Reverse: 5'-TTGAGG CATTCACTCACAGC-3' 
3 Forward: 5'-TCAAGGAGGTAACTGAACTGGC-3' 3 146 bp Intronic ~ 
Reverse: 5'-ATCCCCCAATCTTCTTGCTT-3' 
4 Forward: 5'-GCATTCCTTACCATCAAGATGA-3' 4 153 bp Intronic a 
Reverse: 5'-GTGGG GGTACCAAACTACATG-3' 
5 Forward: 5'-TTCCCAACCTTCAATATCTGTT-3' 5 148 bp 356-503 
Reverse: 5'-AGCCCCACGAAAGAATTTCT-3' 
6 Forward: 5'-AGAAATTCTTTCGTGGGGCT-3' 6-9 357 bp 1484-1840 
Reverse: 5'-GTTTGCAAAGGCACAGCAAT-3' 
7 Forward: 5'-GTTATFTCAGATGGCTGAATAAG-3' 7 78 bp Intronic ~ -592 
Reverse: 5'-GCTCATCTAGTTGGGTTC-3' 
8 Forward: 5'-GCCTGCTAACCAAGAGCACT-3' 9 270 bp Intronic ~ 
Reverse: 5'-AGGATG GACTCACATTTG CC-3' 
9 Forward: 5'-CTACCCTGCACAAAGACAGTG-3' 10 272 bp Intronica-1048 
Reverse: 5'-GCTTAGGG GAGCAGGTCAC-3' 
10 Forward: 5'-GC-clamp-GACTTATGCAATGAAGTGGTTG-3' 10 341 bp b 1006-1346 
Reverse: 5'-GTGAAAAAGCCAGCAGCATC-3' 
11 Forward: 5'-GC-clamp-ATTGACTGGCAAACTGGGG-3' 10 396 bp b 1300-1695 
Reverse: 5'-AGAGGAGG ACACGATGTTG G-3' 
12 Forward: 5'-GC-clampGGCTGCTATATCCACATCTACC-3' 10 201 bp b 1639-1839 
Reverse: 5'-CAGAACCAGCAGAATCTI-FGC-3' 
13 Forward: 5'-GC-clamp-CTTTCTTTGCCATTTCTGCC-3' 10 378 bp b 1766-2143 
Reverse: 5'-CAAAGGCAAGGACTGAATTATC-3' 
14 Forward: 5'-AG CAAAG ATTCTGCTGGTTC-3' 10 326 bp 1818-2143 
Reverse: 5'-13.r 
15 Reverse: 5'-TAGTTTTGG GCTAAATGACTTAGAGGG-3' 
16 Forward: 5'-CCTGCTCCTGGTCTCTTTGCTG-3' 6-2087 
17 5'-GAGTGCACCATGGGCGGTGTGAAAT-3' 
18 5'-GGGATTCAAGAAATACACAACTGTG TATTCAATGGAACCC-3' 
a Unpublished intronic sequence. 
b Without GC clamp. 
DNA Sequencing of PCR Products 
To sequence amplified PCR products, the previously described prim- 
ers were used. Each reaction contained 2 pmol of primer end-labeled 
with [./-32P]ATP (specific activity, 5000 Ci/mmol; Amersham Interna- 
tional), 15 ng of amplified template DNA, and 1 U of Dynazyme (Finn- 
zymes). 
Restriction Enzyme Analysis to Detect the Mutation 
Genomic DNA was amplified as described above. To screen individu- 
als for the C566T mutation, 20 U of Bsml (Promega) was used to digest 
15 I~1 of PCR product. The digestion product was electrophoresed 
through a 10% nondenaturing polyacrylamide gel and DNA visualized 
with ethidium bromide. 
Preparation of the Wild-Type FSHR Expression Construct, and 
Site-Directed Mutagenesls 
The human FSHR cDNA was obtained by RT-PCR by using testicular 
poly(A ÷) RNA, and the resulting cDNA was subcloned into pBluescript 
SK(-) (Stratagene). The primer and conditions are described else- 
where (Gromoll et al., 1992). The 5' untranslated region containing a 
stop codon was deleted, and a perfect consensus sequence for the 
initiation of translation was constructed (Gudermann et al., 1994; Ko- 
zak, 1989). This procedure resulted in a construct comprising 2088 
bp of the translated region of the FSHR and an additional 5-base 5' 
extension and a 92-base 3' extension. The construct was excised by 
digestion with SmaI-Kpnl and blunt end-ligated into the blunted EcoRI 
restriction site of the pSG5 vector (Stratagene). Both strands of the 
cloned cDNA were sequenced by the dideoxy chain termination 
method applying the primer walk technique (Sambrook et al., 1989). 
A plasmid containing the mutated FSHR (T566) was created by 
site-directed mutagenesis using the wild-type FSHR cDNA as tem- 
plate. Oligonucleotide-directed mutagenesis was done according to 
the instructions of the manufacturer (Clontech). The selection primer 
(Table 2, primer 17) transforms an Ndel site into an Ncol site in the 
vector sequence. The primer for mutagenesis in the FSHR cDNA se- 
quence (Table 2, primer 18) transforms C to T at nucleotide 566. The 
identity of the plasmids generated (pFSHR(C566), wild type, and 
pFSHR(T566), mutated) was verified by restriction endonuclease di- 
gestion and sequencing. 
The cell line used for transfection (MSC-1) was derived from a 
transgenic mouse Sertoli cell tumor generated by expressing the sim- 
ian virus 40 (SV40) T antigen under the anti-MLillerian hormone pro- 
moter (Peschon et al., 1992). Despite their Sertoli cell origin, the cells 
do not express endogenous FSHR. Cells in exponential growth phase 
were transiently transfected in DMEM/F12(1:1) medium by use of lipo- 
fectin (GIBCO Life Technologies, Incorporated), as instructed by the 
manufacturer, using either of the above FSHR expression plasmids, 
or buffer for mock transfection. In addition, a cotransfection with a 
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luciferase-expressing pCMV-luci plasmid was done to control the 
transfection efficiency. 
cAMP Production of the Transfected MSC-1 Cells 
Subsequently, 72 hr after transfection, the cells in the 2 cm culture 
plates were challenged, in triplicate, with each of the following concen- 
trations of rhFSH (Org 32489, approximately 10,000 IU/mg, Organon 
International): 0, 2, 10, 50, 100, or 200 IU/liter. After a 3 hr stimulation 
period, the cells and media were removed from the culture plates and 
divided into two equal aliquots. One was diluted 1:1 with 2 mmol/liter 
teophylline, heated at 100°C for 5 min, and subsequently used for 
measurement of cAMP (see below). Supernatants were used for lucif- 
erase assay according to the protocols of Sambrook et al. (1989). The 
light production was measured with a 1251 luminometer (Bio-Orbit). 
For cAMP measurement, a radioimmunoassay was used as described 
before (Harper and Brooker, 1975; Brooker et al., 1979). 
FSH Binding Assay 
The MSC-1 cells cultured in 9 cm diameter culture plates and 
transfected with the FSHR expression plasmids were used for FSH 
binding measurements 48 hr following the transfections. The cells 
were recovered and reconstituted to a concentration of 2 x 108 cells/ 
ml in buffer, rhFSH was radioiodinated with sodium [12~l]iodide with a 
solid-phase lactoperoxidase method (Karonen et al., 1975) to a specific 
activity of 30 Ci/g and 20% specific binding of radioactivity to an excess 
of FSHRs, as determined according to the protocols of Catt et al, 
(1976). Triplicate aliquots of 100 p_l of the cell suspensions (containing 
2 x 10 s cells) were incubated in the presence of 3.13, 6.25, 12.5, 25, 
50, or 100 ng of the radioiodinated rhFSH in a total volume of 250 p.I. 
Nonspecific binding at each hormone concentration was determined 
in the presence of 1.5 IU of rhFSH. After overnight incubation at room 
temperature, the radioactivity of the cell pellets was counted in a 
y-spectrometer. 
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